{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:27:46Z","timestamp":1792585666321,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.102071","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T13:54:47Z","timestamp":1701093287000},"page":"102071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a\u00a0prospective observational study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-0077","authenticated-orcid":false,"given":"Y.","family":"Narita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-8965","authenticated-orcid":false,"given":"Y.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9516","authenticated-orcid":false,"given":"T.","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-5325","authenticated-orcid":false,"given":"N.","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-3757","authenticated-orcid":false,"given":"T.","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-5904","authenticated-orcid":false,"given":"Y.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-9811","authenticated-orcid":false,"given":"M.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-2895","authenticated-orcid":false,"given":"T.","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2023.102071_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10111","key":"10.1016\/j.esmoop.2023.102071_bib2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102071_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","article-title":"Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: a Retrospective Administrative Claims Database Study","volume":"39","author":"Komatsu","year":"2022","journal-title":"Adv Ther"},{"issue":"13","key":"10.1016\/j.esmoop.2023.102071_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102071_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-016-3138-z","article-title":"Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer","volume":"78","author":"Kawakami","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102071_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10120-017-0759-9","article-title":"Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer","volume":"21","author":"Makiyama","year":"2018","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102071_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10120-016-0670-9","article-title":"Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes","volume":"20","author":"Nishimura","year":"2017","journal-title":"Gastric Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102071_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jjco\/hys084","article-title":"Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study","volume":"42","author":"Tsuji","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102071_bib9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s10120-018-0825-y","article-title":"Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan","volume":"21","author":"Kondoh","year":"2018","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102071_bib10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102071_bib11","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s12325-020-01358-2","article-title":"A\u00a0phase II study of modified FOLFOX6 for advanced gastric cancer refractory to standard therapies","volume":"37","author":"Mitani","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102071_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102071_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2023.102071_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102071_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","article-title":"Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer","volume":"73","author":"Szabados","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102071_bib16","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.21873\/anticanres.14187","article-title":"Efficacy of cytotoxic agents after progression on anti-PD-(L)1 antibody for pre-treated metastatic gastric cancer","volume":"40","author":"Kato","year":"2020","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102071_bib17","article-title":"Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102071_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1634\/theoncologist.2013-0306","article-title":"Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912","volume":"19","author":"Takahari","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102071_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247645","article-title":"Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer","volume":"16","author":"Tokuyama","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102071_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.annonc.2022.03.274","volume":"33","author":"Hacker","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102071_bib21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2217\/fon-2020-0621","article-title":"REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer","volume":"17","author":"Narita","year":"2021","journal-title":"Future Oncol (London, England)"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102071_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102071_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00384-006-0259-6","article-title":"Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer","volume":"22","author":"Mcmillan","year":"2007","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102071_bib25","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102071_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"issue":"10294","key":"10.1016\/j.esmoop.2023.102071_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2023.102071_bib28","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"Br Med J (Clinical research ed.)"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102071_bib29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102071_bib30","first-page":"2295","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J\u00a0Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102071_bib31","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2023.102071_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4650695","article-title":"Oxaliplatin treatment alters systemic immune responses","volume":"2019","author":"Stojanovska","year":"2019","journal-title":"BioMed Res Int"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102071_bib33","first-page":"2032","article-title":"Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells","volume":"7","author":"Suzuki","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102071_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J\u00a0Thor Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102071_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102071_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events\u00a0(DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923013121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923013121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:34:27Z","timestamp":1761856467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923013121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923013121"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102071","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a\u00a0prospective observational study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102071"}}